Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 10841 - 10848 of 12011 results

Software and Business Methods — Patentable Subject-Matter in Europe?
October 21, 2013| Advisory| Viewpoint

Treasury Department/IRS Issue Proposed Rules on Employer Reporting of Health Insurance Coverage Under the Affordable Care Act
October 21, 2013| Advisory| Viewpoint

Down the Rabbit Hole: Primary Jurisdiction Redux
October 21, 2013| Blog| Viewpoint

Insider Trading: Lessons from the Mark Cuban Jury Verdict
October 18, 2013| Blog| Viewpoint

Government Shutdown Aftermath: CMS Under Pressure to Finalize Medicare Payment Rules
October 18, 2013| Alert| Viewpoint

Should we worry about Safe Harbor being suspended because of the NSA’s PRISM Program?
October 18, 2013| Blog| Viewpoint

Apocalypse Averted Again: Preliminary Thoughts on Welcoming Workers Back From the Government Shutdown
October 18, 2013| Blog| Viewpoint

End to Government Shutdown Heralds Resumption of US Immigration Processing
October 17, 2013| Alert| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
